July 2008 Volume 5 Number 7
Visit Nature Clinical Practice Oncology online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0UgF0EG
=====================================================================
Before the roundworm, there was the silkmoth.
CDD's next Special Issue commemorates Richard Lockshin in honor of
his 70th birthday.
Featured review articles discuss the phylogeny and regulation of
programmed cell death in a variety of model organisms. Read a selection
of FREE articles from the Richard Lockshin issue online at CDD.
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Bugw0Eh
=====================================================================
----------------------
EDITORIAL
----------------------
Lost in translation-prognostic signatures for breast cancer
Lajos Pusztai
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0ByfW0EE
----------------------
RESEARCH HIGHLIGHTS
----------------------
SATB1 expression generates gene-expression profiles that promote breast
tumor metastasis
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0ByfX0EF
IMP3 expression determines aggressive superficial urothelial carcinoma
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0ByfY0EG
Pfetin predicts outcome for patients with gastrointestinal stromal tumors
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0ByfZ0EH
KRAS wild-type status predicts response to cetuximab in metastatic
colorectal cancer
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfa0EO
Young patients with multiple myeloma have favorable prognostic factors
and better survival
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfb0EP
No survival benefit in follicular lymphoma with first-line intensive
chemoimmunotherapy
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfc0EQ
High lymph-node yield improves the prognostic value of esophageal cancer
staging
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfd0ER
Imiquimod 5% cream treats vulvar intraepithelial neoplasia effectively
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfe0ES
Molecular markers prognostic for biochemical failure in prostate cancer
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byff0ET
----------------------
PRACTICE POINTS
----------------------
Prognosis and outcomes of lymphocyte-predominant Hodgkin's lymphoma
Grace Suh and Anas Younes
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfg0EU
S-1 adjuvant chemotherapy for advanced gastric cancer
David Kelsen
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfh0EV
Does lenalidomide plus dexamethasone improve outcome in patients with
relapsed multiple myeloma?
Madhav V Dhodapkar and Dennis L Cooper
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfi0EW
Lenalidomide plus dexamethasone is efficacious in patients with relapsed
or refractory multiple myeloma
Nikhil C Munshi, Constantine Mitsiades, Paul G Richardson and
Kenneth C Anderson
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfj0EX
----------------------
VIEWPOINT
----------------------
Advantages of multiple clinical tests for determining the optimum
treatment strategy for ER-positive breast cancer
Henrik J Ditzel and Maria B Lyng
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfk0EY
----------------------
REVIEWS
----------------------
Biomarkers of angiogenesis for the development of antiangiogenic therapies
in oncology: tools or decorations?
Cristiana Sessa, Aymeric Guibal, Gianluca Del Conte and Curzio Ruegg
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfl0EZ
Mechanisms of Disease: the role of stem cells in the biology and treatment
of gliomas
Jorg Dietrich, Jaime Imitola and Santosh Kesari
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfm0Ea
Technology Insight: image-guided robotic radiosurgery-a new approach for
noninvasive ablation of spinal lesions
Pantaleo Romanelli and John R Adler Jr
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfn0Eb
Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with
promising clinical activity in colorectal cancer
Max Mano and Yves Humblet
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfo0Ec
----------------------
CASE STUDY
----------------------
Lumpectomy and partial breast irradiation for early-stage breast cancer
following mantle irradiation for Hodgkin's lymphoma
Mohamed A Alm El-Din, Jennifer K Feng and Alphonse G Taghian
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Byfp0Ed
=====================================================================
ESO e-grandround
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0BrPN0Ea
The European School of Oncology in partnership with Nature Clinical
Practice Oncology is pleased to announce live e-grandrounds. These
online discussion-based presentations allow participants to submit
questions and take part in lively discussions. We invite you to join
the e-grandrounds, which are broadcast every other Thursday from
17:15-18:00 GMT.
Please visit http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Boj10EU
for further information.
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/elvN0Xztnp0HjM0Zzu0ER
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
=====================================================================
